Want to join the conversation?
$MYL, which competes with $PFE, $JNJ and $GSK, said that R&D expense for 4Q15 and full-year 2015 rose due to the impact of the acquired EPD business and the continued development of respiratory, insulin and biologics programs. Adjusted SG&A was approx. 20% of total adjusted revenues for 4Q15 and 2015, which includes the impact of the EPD business.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?